Lin BioScience, Inc.
6696
Hisse Senetlerindeki Sıralama
#3878
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Hisse Fiyatı
$5.14
Piyasa Değeri
$4.26B
Değişim (1 gün)
-3.79%
Değişim (1 yıl)
-43.53%
Ülke
TW
Ticaret Lin BioScience, Inc. (6696)
Kategori
Healthcare
Lin BioScience, Inc. (6696) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $5.41 - 2026-10-01
Gün sonu en düşük fiyat: $1.30 - 2018-10-01
Gün sonu en düşük fiyat: $1.30 - 2018-10-01
Lin BioScience, Inc. için hisse fiyatı geçmişi: 2018 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | -4.14% |
| 2025 | 202.95% |
| 2024 | 13.59% |
| 2023 | -31.65% |
| 2022 | -22.82% |
| 2021 | 101.12% |
| 2020 | 278.57% |
| 2019 | -21.27% |
| 2018 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.17 | -4.24% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
